Sage sues Biogen in wake of $469M buyout offer: report
Sage (SAGE) is reportedly suing Biogen (BIIB) over enforcement of a standstill agreement in the wake of an unsolicited ...
Biogen (BIIB) Receives a Hold from Piper Sandler
In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...
Pharma digs in on changes it wants from Trump administration
The pharmaceutical industry, grappling with new government limits on drug prices, is focusing its requests for ...
Biogen Hold Rating: Balancing Promising Prospects with Market Uncertainties
BTIG analyst Thomas Shrader has maintained their neutral stance on BIIB stock, giving a Hold rating on January 14.Stay Ahead of the ...
Biogen Inc. stock underperforms Wednesday when compared to competitors
Shares of Biogen Inc. BIIB shed 1.44% to $141.00 Wednesday, on what proved to be an all-around positive trading session for ...
Hosted on MSN4d
Biogen Announces New Chief Accounting Officer Appointment
Biogen ( ($BIIB) ) has issued an update. On January 13, 2025, Biogen Inc. announced the appointment of Sean Godbout as Vice ...
Biogen CEO sees no burning need for more acquisitions
Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional ...
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money ...
Benzinga.com5d
FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi
Goldman Sachs analyst Salveen Richter believes the proposal makes strategic sense, considering the financial success of the ...
Biogen, Eisai say injectable Alzheimer’s therapy granted FDA review
Biogen (BIIB) and Eisai's (ESALF) (ESAIY) announce that U.S. FDA agreed to review their subcutaneous form of Alzheimer's ...
The risk of dementia is even worse than we thought, new research says
The lifetime risk of dementia after age 55 is about 42% - more than double the risk reported by earlier studies, and one that puts greater urgency on the need to mitigate addressable health problems, ...
Biogen Inc. stock underperforms Monday when compared to competitors despite daily gains
The stock's rise snapped a three-day losing streak.